Proactive Investors - Run By Investors For Investors

Antibe Therapeutics hosts successful annual and special general meeting

The firm said shareholders elected six directors at its annual general meeting
pills
Antibe's lead drug, ATB-346, targets acute and chronic pain associated with osteoarthritis and its Phase 2B dose-ranging efficacy study for the drug remains on track

Antibe Therapeutics (CVE:ATE) (OTCMKTS:ATBPF) released a shareholder update Tuesday, which highlighted its annual general and special meeting, noting all resolutions outlined in the management information circular were approved. 

The firm noted shareholders elected a number of directors: Roderick Flower, Amal Khouri, Daniel Legault, Walt Macnee, John Wallace and Yung Wu. 

Shareholders also approved the reappointment of Ernst & Young LLP, Chartered Accountants, as Antibe's auditor, as well as an amendment to the restricted share unit plan. 

READ: Antibe Therapeutics updates on Phase 2 progress of lead drug ATB-346

Antibe's lead drug, ATB-346, targets acute and chronic pain associated with osteoarthritis and its Phase 2B dose-ranging, efficacy study for the drug remains on track.

The firm is developing a platform of unique drugs to prevent gastrointestinal damage and bleeding caused by using non-steroidal anti-inflammatory drugs known as NSAIDs, which are currently the primary therapy for pain relief. 

Shares of Antibe were at C$0.32 on Tuesday. 

Contact Katie Lewis at [email protected]

View full ATE profile View Profile

Antibe Therapeutics Timeline

Related Articles

researcher at microscope
May 24 2019
Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors
antibodies
May 02 2019
Avacta is using Affimers to develop its own cancer therapy, but it also licenses the technology to other companies, including major pharma group ModernaTX and LG Chem Life Sciences
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use